CA
LXRX icon

Clearstead Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Clearstead Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$240 Buy
+100
New +$195 ﹤0.01% 3143

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Clearstead Advisors's LXRX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Lexicon Pharmaceuticals (LXRX) in Q2 2026: 100 shares worth $240. The stake represents ﹤0.01% of the portfolio and ranks #3143 among its holdings.

149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Clearstead Advisors held 100 shares of Lexicon Pharmaceuticals worth $240 as of Q2 2026.
  • Lexicon Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3143 holding.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.